TUESDAY, Sept. 3, 2024 -- The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects...
Vous n'êtes pas connecté
FRIDAY, July 12, 2024 -- Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight loss, according to new analysis conducted by Prime...
TUESDAY, Sept. 3, 2024 -- The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects...
FRIDAY, Aug.30, 2024 -- New trials are showing how the blockbuster diabetes and weight-loss meds Ozempic and Wegovy can boost health in even more...
Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in the treatment of medlinktype 2 diabetes/medlink and...
Semaglutide – contained in Ozempic and Wegovy – has ‘far-reaching benefits’, with people dying at lower rate from all causes
LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...
MONDAY, Sept. 9, 2024 -- A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the...
Pharmaceuticals such as Ozempic, Wegovy and Mounjaro aren't risk-free. The FDA says it has received reports of people overdosing on compounded...
Pharmaceuticals such as Ozempic, Wegovy and Mounjaro aren't risk-free. The FDA says it has received reports of people overdosing on compounded...
learn about suicide and self-harm risks among users of GLP-1 receptor agonists for type 2 diabetes, obesity, and mental health outcomes
learn about suicide and self-harm risks among users of GLP-1 receptor agonists for type 2 diabetes, obesity, and mental health outcomes